Efficacia e tollerabilità del Levetiracetam in monoterapia in adolescenti con epilessia generalizzata idiopatica

Translated title of the contribution: Efficacy and tolerability of Levetiracetam monotherapy in adolescents with idiopathic generalized epilepsy

C. Cerminara, R. Cusmai, S. Seri, R. Bombardieri, M. Pinci, F. Vigevano, P. Curatolo

Research output: Contribution to journalArticle

Abstract

Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.

Original languageItalian
Pages (from-to)177-178
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number129-130
Publication statusPublished - 2005

Fingerprint

etiracetam
Epilepsy
Seizures
Pyrrolidinones
Valproic Acid
Random Allocation
Idiopathic Generalized Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Efficacia e tollerabilità del Levetiracetam in monoterapia in adolescenti con epilessia generalizzata idiopatica. / Cerminara, C.; Cusmai, R.; Seri, S.; Bombardieri, R.; Pinci, M.; Vigevano, F.; Curatolo, P.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 129-130, 2005, p. 177-178.

Research output: Contribution to journalArticle

@article{5e0fe401aa40447994640f96e0e32220,
title = "Efficacia e tollerabilit{\`a} del Levetiracetam in monoterapia in adolescenti con epilessia generalizzata idiopatica",
abstract = "Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.",
keywords = "Adolescent, Idiopatic epilepsy, Monotherapy, Photosensitivity",
author = "C. Cerminara and R. Cusmai and S. Seri and R. Bombardieri and M. Pinci and F. Vigevano and P. Curatolo",
year = "2005",
language = "Italian",
pages = "177--178",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "129-130",

}

TY - JOUR

T1 - Efficacia e tollerabilità del Levetiracetam in monoterapia in adolescenti con epilessia generalizzata idiopatica

AU - Cerminara, C.

AU - Cusmai, R.

AU - Seri, S.

AU - Bombardieri, R.

AU - Pinci, M.

AU - Vigevano, F.

AU - Curatolo, P.

PY - 2005

Y1 - 2005

N2 - Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.

AB - Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.

KW - Adolescent

KW - Idiopatic epilepsy

KW - Monotherapy

KW - Photosensitivity

UR - http://www.scopus.com/inward/record.url?scp=33645231818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645231818&partnerID=8YFLogxK

M3 - Articolo

SP - 177

EP - 178

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 129-130

ER -